Reference - Detail
|Author||Yamanaka R, Zullo SA, Ramsey J, Yajima N, Tsuchiya N, Tanaka R, Blaese M, Xanthopoulos KG.|
|Title||Marked enhancement of antitumor immune responses in mouse brain tumor models by genetically modified dendritic cells producing Semliki Forest virus-mediated interleukin-12.|
OBJECT:The authors evaluated dendritic cell (DC)-based immunotherapy for malignant brain tumor to improve its therapeutic efficacy.
METHODS:Dendritic cells were isolated from bone marrow and pulsed with phosphate-buffered saline, Semliki Forest virus (SFV)-LacZ, retrovirus vector GCsap-interleukin (IL)-12, and SFV-IL-12, respectively, to treat mice bearing brain tumors of the B16 cell line. The results indicated that therapeutic immunization with DCs pulsed with SFV-IL-12 prolonged the survival of mice with established tumors. Semliki Forest virus induced apoptosis in DCs, which in turn facilitated the uptake of apoptotic cells by other DCs, thus providing a potential mechanism for enhanced immunogenicity.
CONCLUSIONS:Therapy with DCs that have been pulsed with SFV-mediated IL-12 may be an excellent step in the development of new cancer vaccines. Intratumorally injected DCs that have been transiently transduced with IL-12 do not require pulsing of a source of tumor antigens to induce tumor regression.
|MeSH||Animals Apoptosis / immunology Bone Marrow Cells Brain Neoplasms / immunology Brain Neoplasms / therapy* CD4-Positive T-Lymphocytes / immunology CD4-Positive T-Lymphocytes / metabolism CD8-Positive T-Lymphocytes / immunology Dendritic Cells / immunology* Dendritic Cells / virology Genetic Therapy Genetic Vectors Glioma / immunology Glioma / therapy* Immunotherapy, Active Interferon-gamma / biosynthesis Interleukin-12 / genetics* Interleukin-12 / immunology* Mice Mice, Inbred C57BL Semliki forest virus / genetics* Transduction, Genetic Tumor Cells, Cultured / transplantation|
|WOS Category||SURGERY CLINICAL NEUROLOGY|
|Human and Animal Cells|